DE60001492D1 - Pharmazeutische aerosolformulierung - Google Patents

Pharmazeutische aerosolformulierung

Info

Publication number
DE60001492D1
DE60001492D1 DE60001492T DE60001492T DE60001492D1 DE 60001492 D1 DE60001492 D1 DE 60001492D1 DE 60001492 T DE60001492 T DE 60001492T DE 60001492 T DE60001492 T DE 60001492T DE 60001492 D1 DE60001492 D1 DE 60001492D1
Authority
DE
Germany
Prior art keywords
pharmaceutical aerosol
formulations
aerosol formulation
relates
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60001492T
Other languages
English (en)
Other versions
DE60001492T2 (de
Inventor
Isabelle Bonvoisin
Christophe Laroche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921289.6A external-priority patent/GB9921289D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60001492D1 publication Critical patent/DE60001492D1/de
Publication of DE60001492T2 publication Critical patent/DE60001492T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60001492T 1999-04-14 2000-04-13 Pharmazeutische aerosolformulierung Expired - Fee Related DE60001492T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BH12699 1999-04-14
GBGB9921289.6A GB9921289D0 (en) 1999-09-10 1999-09-10 Pharmaceutical aerosol formulation
PCT/GB2000/001418 WO2000061108A1 (en) 1999-04-14 2000-04-13 Pharmaceutical aerosol formulation

Publications (2)

Publication Number Publication Date
DE60001492D1 true DE60001492D1 (de) 2003-04-03
DE60001492T2 DE60001492T2 (de) 2003-12-18

Family

ID=25663377

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60001492T Expired - Fee Related DE60001492T2 (de) 1999-04-14 2000-04-13 Pharmazeutische aerosolformulierung

Country Status (10)

Country Link
US (1) US7090831B1 (de)
EP (1) EP1169019B1 (de)
JP (1) JP2002541183A (de)
AT (1) ATE233084T1 (de)
AU (1) AU4417500A (de)
DE (1) DE60001492T2 (de)
DK (1) DK1169019T3 (de)
ES (1) ES2193069T3 (de)
PT (1) PT1169019E (de)
WO (1) WO2000061108A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064613A1 (en) * 2006-09-11 2008-03-13 M-I Llc Dispersant coated weighting agents
ES2689704T3 (es) * 2000-11-30 2018-11-15 Vectura Limited Partículas para usar en una composición farmacéutica
US8048451B2 (en) * 2000-11-30 2011-11-01 Vectura Limited Pharmaceutical compositions for inhalation
PL204659B1 (pl) * 2000-12-22 2010-01-29 Glaxo Group Ltd Pojemnik do inhalatora dozującego
WO2003024452A1 (de) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation
CN1674874A (zh) * 2002-08-14 2005-09-28 纳幕尔杜邦公司 涂覆药物颗粒的方法
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN1791386A (zh) * 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
GB0321607D0 (en) † 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
EP1688169A4 (de) * 2003-11-28 2008-10-01 Mitsubishi Chem Corp Verfahren zur herstellung von feinen teilchen einer organischen verbindung
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JPWO2009069619A1 (ja) * 2007-11-27 2011-04-14 株式会社Ｅｒｃテクノロジー オゾン化界面活性剤を含有する新規組成物
CN104523661A (zh) 2009-02-06 2015-04-22 南加利福尼亚大学 含有单萜的治疗组合物
KR20170070274A (ko) 2009-05-29 2017-06-21 펄 테라퓨틱스 인코포레이티드 지속형 무스카린 안타고니스트 및 지속형 ｂ₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
HUE026414T2 (hu) 2009-07-15 2016-05-30 Theravance Biopharma R&D Ip Llc Bifenil-vegyület kristályos szabad-bázis formája
EP2542082B8 (de) 2010-03-03 2020-06-17 Neonc Technologies Inc. PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT (S)-Perillylalkohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
US9211269B2 (en) 2010-12-17 2015-12-15 Neonc Technologies Inc. Methods and devices for using isoperillyl alcohol
HUE042556T2 (hu) 2011-10-11 2019-07-29 Chiesi Farm Spa Zsírsavval bevont béta-agonista kristályos mikrorészecskéi
DK2968312T3 (en) 2013-03-15 2018-05-07 Verona Pharma Plc drug combination
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
DE102013021718B4 (de) * 2013-12-20 2017-03-02 Gerresheimer Regensburg Gmbh Kapsel zur Verwendung als Reservoir für eine pharmazeutische, vorzugsweise pulverförmige Zubereitung in einem Inhalator sowie Inhalator dafür
EP3142701B1 (de) 2014-05-12 2018-06-27 Verona Pharma PLC Neue behandlung
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
US10858305B2 (en) 2016-11-30 2020-12-08 Neonc Technologies, Inc. Perillyl alcohol-3-bromopyruvate conjugate and methods of treating cancer
CN111936125A (zh) 2018-02-08 2020-11-13 尼昂克技术公司 穿透血脑屏障的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1535531A (en) * 1976-10-15 1978-12-13 Warmer & Co Ltd W Pharmaceutical compositions
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
EP0318492A1 (de) 1986-08-11 1989-06-07 Innovata Biomed Limited Mikrokapseln enthaltende pharmazeutische zusammensetzungen
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
EP0527940A1 (de) 1990-05-08 1993-02-24 Liposome Technology, Inc. Direkt sprühgetrocknetes arzneistoff/lipid pulver
GB9024365D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9024366D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9026005D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2381329C (en) 1991-12-12 2003-04-15 Glaxo Group Limited Medicaments
EP0550031B1 (de) 1991-12-31 1996-05-08 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
EP0655237A1 (de) 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
JPH08151322A (ja) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd 経口徐放剤
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5985248A (en) 1996-12-31 1999-11-16 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs and compositions thereof
BR9909736A (pt) 1998-04-18 2000-12-19 Glaxo Group Ltd Formulação farmacêutica de aerossol, processo para preparação de uma formulação farmacêutica de aerossol, partìculas de princìpios ativos farmacêuticos, e, cartucho
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process

Also Published As

Publication number Publication date
ATE233084T1 (de) 2003-03-15
DK1169019T3 (da) 2003-06-02
ES2193069T3 (es) 2003-11-01
WO2000061108A1 (en) 2000-10-19
EP1169019A1 (de) 2002-01-09
DE60001492T2 (de) 2003-12-18
EP1169019B1 (de) 2003-02-26
JP2002541183A (ja) 2002-12-03
PT1169019E (pt) 2003-07-31
AU4417500A (en) 2000-11-14
US7090831B1 (en) 2006-08-15

Similar Documents

Publication Publication Date Title
DE60001492D1 (de) Pharmazeutische aerosolformulierung
AP2000001961A0 (en) Pharmaceutical aerosol formulation.
ES2178817T3 (es) Formulaciones medicinales de aerosol.
ATE342048T1 (de) Neue aerosolformulierungen ein polares fluoriniertes molekül enthaltend
ME00333B (me) Farmaceutski aerosolni preparat
NO20010391D0 (no) Medisinske aerosolformuleringer
DK0553298T3 (da) Aerosolformulering omfattende beclomethason-17,21-dipropionat
DK1086688T3 (da) Aerosolformuleringer til suspensioner
HUP0103925A2 (hu) Formoterolt tartalmazó, stabilan tárolható hatóanyag-koncentrátum
ATE291898T1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
HUP0002691A2 (hu) Ciklezonid tartalmú gyógyászati aeroszol termékek
ATE398999T1 (de) Aerosol-formulierungen von formoterol und mometason
HUP0000795A2 (hu) Budeszonidot tartalmazó, aeroszol formájú gyógyszerkészítmény
CA2441549A1 (en) Ipratropium formulation for pulmonary inhalation
CO4900027A1 (es) Formulaciones en aerosol de furoato de mometasona sin cloro- fluorocarburos .
WO1999024016A8 (en) Emulsions for aerosolization and drug delivery
EP1523976A3 (de) Pharmazeutische Formulierungen enthaltend Salmeterol
TH29519B (th) สูตรผสมทางเภสัชศาสตร์ที่เสถียรชนิดใหม่สำหรับการผลิตละอองลอยที่ไม่มีแก๊สผลักดัน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee